68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

被引：155
|
作者：
Rauscher, Isabel [1 ,2 ,3 ]
Maurer, Tobias [2 ,4 ]
Fendler, Wolfgang P. [2 ,5 ]
Sommer, Wieland H. [2 ,6 ]
Schwaiger, Markus [1 ,2 ,3 ]
Eiber, Matthias [1 ,2 ,3 ]
机构：
[1] Tech Univ Munich, Dept Nucl Med, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany
[2] Clin Canc Ctr Munich CCM, Munich, Germany
[3] German Canc Consortium DKTK, Heidelberg, Germany
[4] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany
[5] Univ Munich, Dept Nucl Med, Marchioninistr 15, D-81377 Munich, Germany
[6] Univ Munich, Dept Clin Radiol, Grosshadern Campus,Marchioninistr 15, D-81377 Munich, Germany
来源：
CANCER IMAGING | 2016年 / 16卷
关键词：
Prostate cancer; Prostate specific membrane antigen; Positron emission tomography; GA-68-LABELED PSMA LIGAND; MEMBRANE ANTIGEN; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; LYMPH-NODES; HBED-CC; DIAGNOSIS; EXPRESSION; CARCINOMA; TOMOGRAPHY;
D O I：
10.1186/s40644-016-0072-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with Ga-68-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with Ga-68-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of Ga-68-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.
引用
收藏
页数：10
相关论文
共 50 条
  • [41] Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer
    Freitag, Martin T.
    Radtke, Jan P.
    Hadaschik, Boris A.
    Kopp-Schneider, A.
    Eder, Matthias
    Kopka, Klaus
    Haberkorn, Uwe
    Roethke, Matthias
    Schlemmer, Heinz-Peter
    Afshar-Oromieh, Ali
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (01) : 70 - 83
  • [42] Metastases From Colorectal Cancer Avid on 68Ga-PSMA PET/CT
    Hangaard, Lise
    Jochumsen, Mads Ryo
    Vendelbo, Mikkel Holm
    Bouchelouche, Kirsten
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (07) : 532 - 533
  • [43] Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
    Eiber, Matthias
    Maurer, Tobias
    Souvatzoglou, Michael
    Beer, Ambros J.
    Ruffani, Alexander
    Haller, Bernhard
    Graner, Frank-Philipp
    Kuebler, Hubert
    Haberhorn, Uwe
    Eisenhut, Michael
    Wester, Hans-Juergen
    Gschwend, Juergen E.
    Schwaiger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (05) : 668 - 674
  • [44] Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience
    Okudan, Berna
    Coskun, Nazim
    Seven, Bedri
    Atalay, Merve Agcioglu
    Yildirim, Aslihan
    Gortan, Fatma Arzu
    NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (11) : 1254 - 1260
  • [45] Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer
    Tulsyan, Shruti
    Das, Chandan J.
    Tripathi, Madhavi
    Seth, Amlesh
    Kumar, Rajeev
    Bal, Chandrasekhar
    NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (12) : 1094 - 1102
  • [46] 68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology
    Berger, I
    Annabattula, C.
    Lewis, J.
    Shetty, D., V
    Kam, J.
    Maclean, F.
    Arianayagam, M.
    Canagasingham, B.
    Ferguson, R.
    Khadra, M.
    Ko, R.
    Winter, M.
    Loh, H.
    Varol, C.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (02) : 204 - 211
  • [47] Evaluation of the clinical use of PET/CT with 68Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer
    Braga Ribeiro, Andre Marcondes
    Pereira Lima, Eduardo Nobrega
    Zequi, Stenio de Cassio
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (01) : 73.e9 - 73.e18
  • [48] 68Ga-PSMA PET/CT evaluation in men enrolled in prostate cancer Active Surveillance
    Pepe, Pietro
    Pepe, Ludovica
    Tamburo, Marinella
    Marletta, Giulia
    Savoca, Francesco
    Pennisi, Michele
    Fraggetta, Filippo
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2023, 95 (02) : 31 - 34
  • [49] THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER
    Simsek, Duygu Has
    Isik, Emine Goeknur
    Civan, Caner
    Ozkan, Zeynep Goezde
    Kuyumcu, Serkan
    Iribas, Ayca
    Sanli, Mehmet Oner
    Sanli, Yasemin
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2021, 84 (01): : 48 - 56
  • [50] Detection of Sarcomatoid Lung Metastasis With 68GA-PSMA PET/CT in a Patient With Prostate Cancer
    Geraldo, Llanos
    Ceci, Francesco
    Uprimny, Christian
    Kendler, Dorota
    Virgolini, Irene
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (05) : 421 - 422
12345